To include your compound in the COVID-19 Resource Center, submit it here.
Kamada began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 80 or 160 mg inhaled AAT twice daily
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury